摘要
目的观察吉非替尼单药治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法对50例晚期NSCLC患者给予吉非替尼250 mg／d口服治疗,观察疗效和不良反应,采用欧洲癌症研究和治疗组织生活质量调查核心问卷QLQ-C30和简明乏力量表(BFI)对患者的生活质量及临床症状的改善进行评价,观察疾病进展时间(TTP)和中位生存时间(MST)。结果50例晚期NSCLC患者中,无完全缓解者,部分缓解(PR)8例(16．0％),临床获益率为60．0％,临床获益率与性别、病理类型及吸烟史有关。到随访截止日期,50例患者中,20例(40．O％)存活,其MST为13个月;30例死亡患者TTP为5个月,MST为6个月。PR患者MST为9个月。综合生活质量改善率为58．0％,乏力症状缓解率为52．6％,出现症状缓解的中位时间为15 d。不良反应主要为Ⅰ、Ⅱ度皮疹和腹泻,对症处理后可缓解。3例既往因放疗而引起放射性肺炎的患者中,2例放射性肺炎加重。结论吉非替尼有明显抗肿瘤作用,能明显提高晚期NSCLC患者的生活质量,改善临床症状,不良反应可以耐受。
Objective To study the anti-tumor effect and toxicity of Gefitinib in the treatment of patients with advanced non-small-cell lung cancer （ NSCLC ）. Methods From August 2003 to February 2005, 50 advanced NSCLC patients were treated with Gefitinib orally 250 mg once per clay. All patients were stratified by gender, histology, smoking history and chemotherapy cycles. The response was evaluated as the time to tumor progression （TIP） and the median survival time （MST）. Quality of life （QoL） was assessed using the Chinese version of European Organization for Research and Treatment of Cancer （ EORTC ） core questionnaire QLQ-30 and the brief fatigue inventory （BF1）. Results Even though none of these patients achieved complete response, 16.0% of them still gave partial response. Clinical benefit rate was 60.0% in this series. Objective tumor response was correlated with gender, pathological type and smoking history. Multivariate analysis suggested that gender, chemotherapy cycles and QoL obviously correlated with the tumor response. Twenty of these 50 patients （40.0% , 20/50 ） were still alive when the follow-up ended in February 2005. The 1-year survival rate was 14.0%. TIP and MST was 5 and 6 months, respectively, in patients who had been dead. The median survival time of patients who are still alive was 13 months. The mean survival time of PR patients was more than 9 months. The rate of QoL improvement was 58.0% and the rate of fatigue remission was 52.6%. The mean time to symptom improvement was 15 days. The main toxicities were reversible grade Ⅰ or grade Ⅱ skin rash and diarrhea. Two patients who developed radiation pneumonitis during previous radiotherapy became more deteriorated after Gefitinib treatment. Conclusion Gefitinib is effective and tolerated by the patients with advanced non-small cell lung cancer. It may remarkablely improve their symptoms and quality of life.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2006年第7期539-541,共3页
Chinese Journal of Oncology
关键词
非小细胞肺癌
吉非替尼
靶向治疗
Non-small-cell lung cancer
Gefitinib
Target therapy
